FDA Authorizes Additional Vaccine Dose For Certain Immunocompromised Individuals

Today, the U.S. Food and Drug Administration amended the emergency use authorizations for both the Pfizer-BioNTech and Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals, specifically, solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.